Evidence map›Paper›PMID 35728900›Full record

Trial reportBMJ open2022

Investigation of the use of a sensor bracelet for the presymptomatic detection of changes in physiological parameters related to COVID-19: an interim analysis of a prospective cohort study (COVI-GAPP).

Martin Risch, Kirsten Grossmann, Stefanie Aeschbacher, Ornella C Weideli, Marc Kovac, Fiona Pereira, Nadia Wohlwend, Corina Risch, Dorothea Hillmann, Thomas Lung and 19 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Detection of PPB-Level HACS sensors · 2024
    Article
  10. Article
  11. Article
  12. Observational
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 12 institutions in 6 countries.

Martin Risch *Dr Risch Medical Laboratory, Vaduz, Liechtenstein.
Kirsten Grossmann *Dr Risch Medical Laboratory, Vaduz, Liechtenstein.ORCID 0000-0002-0460-3736
Stefanie AeschbacherCardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.
Ornella C WeideliDr Risch Medical Laboratory, Vaduz, Liechtenstein.ORCID 0000-0003-2339-9440
Marc KovacDr Risch Medical Laboratory, Buchs, Switzerland.
Fiona PereiraDepartment of Metabolism, Digestive Diseases and Reproduction, Imperial College London, London, UK.
Nadia WohlwendDr Risch Medical Laboratory, Buchs, Switzerland.
Corina RischDr Risch Medical Laboratory, Buchs, Switzerland.
Dorothea HillmannDr Risch Medical Laboratory, Buchs, Switzerland.
Thomas LungDr Risch Medical Laboratory, Buchs, Switzerland.
Harald RenzInstitute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Marburg, Germany.ORCID 0000-0003-0602-7215
Raphael TwerenboldCardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0003-3814-6542
Martina RothenbühlerAva AG, Zurich, Switzerland.ORCID 0000-0001-8009-4104
Daniel LeibovitzAva AG, Zurich, Switzerland.
Vladimir KovacevicAva AG, Zurich, Switzerland.
Andjela MarkovicAva AG, Zurich, Switzerland.ORCID 0000-0003-2104-9543
Paul KlaverJulius Clinical, Zeist, The Netherlands.
Timo B BrakenhoffJulius Clinical, Zeist, The Netherlands.
Billy FranksJulius Clinical, Zeist, The Netherlands.
Marianna MitratzaUMC Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-1573-2015
George S DownwardUMC Utrecht, Utrecht, The Netherlands.ORCID 0000-0001-6642-7048
Ariel DowlingTakeda Pharmaceuticals, Digital Clinical Devices, Cambridge, UK.ORCID 0000-0002-7889-4978
Santiago MontesRoche Diagnostics Nederland B.V, Almere, The Netherlands.
Diederick E Grobbee *UMC Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-4472-4468
Maureen Cronin *Ava AG, Zurich, Switzerland.
David Conen *Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Brianna M Goodale *Ava AG, Zurich, Switzerland.
Lorenz Risch *Dr Risch Medical Laboratory, Vaduz, Liechtenstein lorenzrisch@hotmail.com.ORCID 0000-0003-2692-6699
COVID-19 remote early detection (COVID-RED) consortium
Labormedizinische Zentrum Dr Risch (Switzerland) · CHUniversity of Liechtenstein · LIUtrecht University · NLYulius · NLUniversity of Basel · CHImperial College London · GBPhilipps University of Marburg · DEPopulation Health Research Institute · CARoche (Netherlands) · NLTakeda (United Kingdom) · GBUniversity of Bern · CHUniversity of Fribourg · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe investigated machinelearningbased identification of presymptomatic COVID-19 and detection of infection-related changes in physiology using a wearable device.

designInterim analysis of a prospective cohort study. SETTING, PARTICIPANTS AND

interventionsParticipants from a national cohort study in Liechtenstein were included. Nightly they wore the Ava-bracelet that measured respiratory rate (RR), heart rate (HR), HR variability (HRV), wrist-skin temperature (WST) and skin perfusion. SARS-CoV-2 infection was diagnosed by molecular and/or serological assays.

resultsA total of 1.5 million hours of physiological data were recorded from 1163 participants (mean age 44±5.5 years). COVID-19 was confirmed in 127 participants of which, 66 (52%) had worn their device from baseline to symptom onset (SO) and were included in this analysis. Multi-level modelling revealed significant changes in five (RR, HR, HRV, HRV ratio and WST) device-measured physiological parameters during the incubation, presymptomatic, symptomatic and recovery periods of COVID-19 compared with baseline. The training set represented an 8-day long instance extracted from day 10 to day 2 before SO. The training set consisted of 40 days measurements from 66 participants. Based on a random split, the test set included 30% of participants and 70% were selected for the training set. The developed long short-term memory (LSTM) based recurrent neural network (RNN) algorithm had a recall (sensitivity) of 0.73 in the training set and 0.68 in the testing set when detecting COVID-19 up to 2 days prior to SO.

conclusionWearable sensor technology can enable COVID-19 detection during the presymptomatic period. Our proposed RNN algorithm identified 68% of COVID-19 positive participants 2 days prior to SO and will be further trained and validated in a randomised, single-blinded, two-period, two-sequence crossover trial.

Indexed as

COVID-19AdultCohort StudiesHumansMiddle AgedProspective StudiesSARS-CoV-2COVID-19Health informaticsHealth & safetyInfection controlPublic healthVIROLOGY

Identifiers

PMID35728900
PMCPMC9240454
OpenAlexW4283257881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.